Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Cited by (1,433)

Items 801–900 of 1,433

1. Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group
   Federico Vozella, A. Siniscalchi, M. Rizzo, Tommaso Zà, Giusy Antolino, Ugo Coppetelli, Alfonso Piciocchi, A Andriani, Ombretta Annibali, Luca De Rosa et al. · 2021 · Annals of Hematology
2. Role and Modulation of NK Cells in Multiple Myeloma
   Marie‐Thérèse Rubio, Adèle Dhuyser, Stéphanie Nguyen · 2021 · Hemato
3. The molecular biology of multiple myeloma
   Wee Joo Chng, Peter Leif Bergsagel · 2019 · Wiley eBooks
4. What The Princess Bride Teaches Us About Outcomes in Multiple Myeloma
   Anita D’Souza, Sagar Lonial · 2021 · Journal of Clinical Oncology
5. Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials
   Fortunato Morabito, Elena Zamagni, Concetta Conticello, Vincenzo Pavone, Salvatore Palmieri, Sara Bringhen, Monica Galli, Silvia Mangiacavalli, Daniele Derudas, Elena Rossi et al. · 2022 · Frontiers in Oncology
6. Predicting progression events in multiple myeloma from routine blood work
   Maximilian Ferle, Nora Grieb, Markus Kreuz, Jonas Ader, Hartmut Goldschmidt, Elias K. Mai, Uta Bertsch, Uwe Platzbecker, Thomas Neumuth, Kristin Reiche et al. · 2025 · npj Digital Medicine
7. Colon perforation in multiple myeloma patients – A complication of high‐dose steroid treatment
   Iuliana Vaxman, Abdullah S. Al Saleh, Shaji Kunnathu Kumar et al. · 2020 · Cancer Medicine
8. Pharmacologic characterization of TBP1901, a prodrug form of aglycone curcumin, and CRISPR-Cas9 screen for therapeutic targets of aglycone curcumin
   Tomoyuki Abe, Yoshihito Horisawa, Osamu Kikuchi, Hitomi Ozawa‐Umeta, Atsuhiro Kishimoto, Yasuhiro Katsuura, Atsushi Imaizumi, Tadashi Hashimoto, Kotaro Shirakawa, Akifumi Takaori‐Kondo et al. · 2022 · European Journal of Pharmacology
9. Progressive multifocal leukoencephalopathy in a patient with multiple myeloma: a case report and analysis of the FDA adverse event reporting system
   Elise Jonasson Nielsen, Ronald Antulov, Per Trøllund Pedersen, Tobias Sejbæk · 2023 · Frontiers in Neurology
10. Harnessing the immunomodulatory effects of exercise to enhance the efficacy of monoclonal antibody therapies against B-cell haematological cancers: a narrative review
    Harrison D. Collier‐Bain, Frankie F. Brown, Adam J. Causer, Annabelle Emery, Rebecca Oliver, Sally E. Moore, James Murray, James E. Turner, John P. Campbell · 2023 · Frontiers in Oncology
11. Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma
    Basudev Chowdhury, Swati Garg, Wei Min NI, Martin Sattler, Dana Sanchez, Chengcheng Meng, Taisei Akatsu, Richard Maury Stone, William C. Forrester, Edmund M. Harrington et al. · 2024 · Cancers
12. Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma
    Parameswaran Hari, Huamao Mark Lin, Yanyan Zhu, Deborah T. Berg, Paul Gerard Guy Richardson, Philippe Moreau · 2018 · Journal of Medical Economics
13. Present and Future of Immunotherapy in the Management of Multiple Myeloma
    Muhamed Baljević, Sarah A. Holstein · 2018 · Journal of Oncology Practice
14. Successful Retreatment with Elotuzumab for Multiple Myeloma with Extramedullary Relapse while Being Treated with Lenalidomide and Dexamethasone
    Satoko Oka, Kazuo Ōno, Masaharu Nohgawa · 2019 · Pathology & Oncology Research
15. Endoplasmic reticulum stress and proteasome inhibitors in multiple myeloma – a room for improvement
    Tadeusz Kubicki, Lidia Gil, Dominik Dytfeld · 2021 · Polskie Archiwum Medycyny Wewnętrznej
16. Cytomegalovirus reactivation in patients with multiple myeloma administered daratumumab-combination regimens
    Rikako Tabata, Nobue Sato, Nobuhiko Yamauchi · 2021 · Annals of Hematology
17. Selinexor for the treatment of patients with previously treated multiple myeloma
    Clifton Craig Mo, Sundar Jagannath, Ajai Chari, Ajay K. Nooka, Sagar Lonial, David Samuel DiCapua Siegel, Noa Biran, Cristina Gasparetto, Nizar Jacques Bahlis, Paul Gerard Guy Richardson · 2021 · Expert Review of Hematology
18. Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database
    Richard LeBlanc, Hira S. Mian, Donna Ellen Reece, Esther Masih‐Khan, Moustafa Kardjadj, Victor Hugo Jimenez-Zepeda, Arleigh B. Robertson McCurdy, Kevin Song, Michaël Sébag, Martha Louzada et al. · 2022 · British Journal of Haematology
19. Toxicity management strategies for next-generation novel therapeutics in multiple myeloma
    Mary Nicole Steinbach, Kelley L. Julian, Brian Lee McClune, Douglas Weston Sborov · 2022 · Therapeutic Advances in Hematology
20. Better resolving of anti‐CD38 antibody interference with blood compatibility testing by using manual polybrene method compared with dithiothreitol‐pretreatment indirect antiglobulin test
    Chiu‐Che Feng, Ci-Wen Chang, Zhi‐Yi Lien · 2023 · Journal of Clinical Laboratory Analysis
21. Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials
    Ye Lu, Fei Zhou, Dongdong Cheng, Ming Xie, Xiaoli Yan, Yuyu Xue, Qian Yang, Rong Jia, Lili Zhong, Li Yang et al. · 2023 · Frontiers in Oncology
22. Multiple Myeloma and Related Disorders
    S. Vincent Rajkumar, Angela A. Dispenzieri · 2020 · Elsevier eBooks
23. Elotuzumab as a novel anti-myeloma immunotherapy
    Sabarinath Venniyil Radhakrishnan, Neelam Bhardwaj, Mary Nicole Steinbach, Janet Weidner, Tim Luetkens, Djordje Atanackovic · 2017 · Human Vaccines & Immunotherapeutics
24. Triplet therapies – the new standard of care for multiple myeloma: how to manage common toxicities
    Agne Paner, Tochukwu M. Okwuosa, Kristin J. Richardson, Edward N. Libby · 2018 · Expert Review of Hematology
25. Mechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma
    Ajay K. Nooka, Sagar Lonial · 2019 · The Cancer Journal
26. Association of Choroidal Effusion and Infusion of Daratumumab
    Peter Kristian Rasmussen, Jens Folke Kiilgaard, Morten Salomo · 2019 · JAMA Ophthalmology
27. Daratumumab added to standard of care in patients with newly diagnosed multiple myeloma: A network meta‐analysis
    Wenjun Xu, Dianfang Li, Yanhua Sun, Xuehong Ran, Baohong Wang, Wei Wu, Zhixin Sheng, Liping Liu · 2019 · European Journal Of Haematology
28. Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation
    on behalf of the European Myeloma Network, Teresa Caballero‐Velázquez, Cristina Calderón‐Cabrera, Lucía López‐Corral, Noemí Puig, Francisco José Márquez-Malaver, Estefanía Pérez‐López, Clara Beatriz García-Calderón, Clara María Rosso-Fernández, Dolores M. Caballero et al. · 2019 · Bone Marrow Transplantation
29. High CD38 expression in childhood T-cell acute lymphoblastic leukemia is not associated with prognosis
    Chan Liao, Diying Shen, Xiaojun Xu, Hua Song, Weiqun Xu, Fenying Zhao, Shi-Long Yang, Yongmin Tang · 2020 · Cancer Biomarkers
30. The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies—back to the future!
    Dickran Gano Kazandjian, Alexander Dew, Elizabeth Hill · 2020 · Best Practice & Research Clinical Haematology
31. Multiple Myeloma in a Young Female Presenting with Neurological Symptoms
    Matthew H. Lee, Xinmin Zhang, Vinh Nghi Nguyen, Monique A. Hartley-Brown · 2020 · Case Reports in Hematology
32. The safety of current and emerging therapies for multiple myeloma
    Omar Nadeem, Kenneth Carl Anderson · 2020 · Expert Opinion on Drug Safety
33. Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany
    Edin Basic, Mathias Kappel, Arpit Misra, Leopold Sellner, Boris A. Ratsch, Dennis Alexander Ostwald · 2020 · The European Journal of Health Economics
34. Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma
    Yvette N. Lamb · 2020 · Drugs
35. A multicenter review of infusion-related reactions to daratumumab for relapsed multiple myeloma in the real world setting
    Marc Geirnaert, Jacy Howarth, Kristen Martin · 2020 · Journal of Oncology Pharmacy Practice
36. Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review
    Laeth L. George, S. Deshpande, Matthew Joseph Cortese, Ellen K. Kendall, Asmi Chattaraj, Zunairah Shah, Jianjun Zhao, Faiz Anwer · 2021 · Clinical Lymphoma Myeloma & Leukemia
37. Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma
    Klaus Podar, Martin Pecherstorfer · 2017 · Expert Opinion on Pharmacotherapy
38. Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion
    Tracy King, Jacqueline Jagger, Jodie Wood, Carmel Woodrow, Alicia Snowden, Sally Haines, Christina Crosbie, Kristen Houdyk · 2018 · Asia-Pacific Journal of Oncology Nursing
39. Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma
    Masuho Saburi, Masao Ogata, Yasuhiro Soga, Yoshiyuki Kondo, Ryo Kurimoto, Kazuhito Itani, Kazuhiro Kohno, Hiroki Uchida, Toshiyuki Nakayama · 2020 · Journal of the Japan Society of the Reticuloendothelial System
40. Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study
    Karthik Ramasamy, Hervé Avet‐Loiseau, Cecilie Hveding Blimark, Michel Delforge, Francesca Gay, Salomon Manier, Joaquín Martínez‐López, María‐Victoria Mateos, Mohamad Mohty, Niels W.C.J. van de Donk et al. · 2023 · HemaSphere
41. New developments in the treatment of multiple myeloma – clinical utility of daratumumab
    Cian McEllistrim, Janusz Krawczyk, Michael E O'Dwyer · 2017 · Biologics
42. Cytomegalovirus infection during daratumumab therapy in patients with newly diagnosed multiple myeloma
    Taku Kikuchi, Nobuhiro Tsukada, Kodai Kunisada et al. · 2024 · International Journal of Hematology
43. Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab‐based regimens
    Danilo De Novellis, Raffaele Fontana, Bianca Serio, Emilia Vaccaro, Roberto Guariglia, Denise Morini, Michela Rizzo, Valentina Giudice, Carmine Selleri · 2024 · Cancer Medicine
44. Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials
    Kwee Yong, Hermann Einsele, Jordan Mark Schecter, Tito Roccia, William M Deraedt, Nikoletta K. Lendvai, Ana Slaughter, Carolina Lonardi, Kaitlyn Connors, Keqin Qi et al. · 2024 · European Journal of Cancer
45. Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study
    Evangelos Terpos, Marco Gobbi, Anna Potamianou, Marjolein Lahaye, Catherine Couturier, Michèle Cavo · 2017 · European Journal Of Haematology
46. Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case‐based approach
    Marc‐Andrea Baertsch, Michael Hundemer, Jens Hillengaß, Hartmut Goldschmidt, Marc Steffen Raab · 2017 · Hematological Oncology
47. Hematopoietic Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Therapies
    Khalid Ahmed Al‐Anazi · 2019 · IntechOpen eBooks
48. High cutoff haemodialysis in myeloma cast nephropathy: further investigation is needed
    Frank Bridoux, Sylvie Chevret, Jean‐Paul Fermand · 2019 · The Lancet Haematology
49. Sudden Cardiac Arrest after Daratumumab Infusion
    Aditya Jandial, Kundan Mishra, Gaurav Prakash, Pankaj Malhotra · 2019 · Indian Journal of Medical and Paediatric Oncology
50. Assessment of Hazard Ratios in Oncology Clinical Trials Terminated Early for Superiority
    Masashi Shimura, Shogo Nomura, Masashi Wakabayashi, Kazushi Maruo, Masahiko Gosho · 2020 · JAMA Network Open
51. Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study
    Shinsuke Iida, Takayuki Ishikawa, Chang‐Ki Min, Kihyun Kım, Su Peng Yeh, Saad Z. Usmani, María‐Victoria Mateos, Hareth Nahi, Christoph Johann Heuck, Xiang Qin et al. · 2021 · Annals of Hematology
52. Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis
    Kazutaka Sunami, Takashi Ikeda, Shang‐Yi Huang, Ming‐Chung Wang, Youngil Koh, Chang Ki Min, Su‐Peng Yeh, Morio Matsumoto, Michihiro Uchiyama, Satoshi Iyama et al. · 2022 · Clinical Lymphoma Myeloma & Leukemia
53. Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma
    Malin L. Hultcrantz, Even Holth Rustad, Venkata D. Yellapantula, Allison P. Jacob, Theresia Akhlaghi, Neha Korde, Sham Mailankody, Alexander M. Lesokhin, Hani Hassoun, Eric L. Smith et al. · 2022 · Clinical Cancer Research
54. Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment
    Gianfranco Lapietra, Francesca Fazio, Maria Teresa Petrucci · 2022 · Biomolecules
55. Molecular Determinants Underlying the Anti-Cancer Efficacy of CD38 Monoclonal Antibodies in Hematological Malignancies
    Nurulhuda Binte Mustafa, Muhamad Irfan Bin Azaman, Giselle G. K. Ng, Wee Joo Chng · 2022 · Biomolecules
56. Daratumumab plus lenalidomide and dexamethasone for relapsed POEMS syndrome with bone plasmacytoma harboring 17p deletion
    Takashi Oyama, Kazuki Taoka, Akira Chiba · 2022 · International Journal of Hematology
57. Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma
    Mattia D’Agostino, Giulia Gazzera, Giusy Cetani, Sara Bringhen, Mario Boccadoro, Francesca Gay · 2018 · Current Medicinal Chemistry
58. Combination of lenalidomide and vitamin D enhances MOR202-mediated cytotoxicity of macrophages: It takes three to tango
    Cindy Flamann, Leonhard Busch, Andréas Mackensen · 2019 · Oncotarget
59. Influence of ABCB1 polymorphisms on the pharmacokinetics and toxicity of lenalidomide in patients with multiple myeloma
    Takahiro Kobayashi, Masatomo Miura, Maiko Abumiya, Yumiko Akamine, Fumiko Ito, Naoto Takahashi · 2019 · Medical Oncology
60. Limited treatment options in refractory multiple myeloma: promising therapeutic developments
    Albert Oriol, Laura Abril, Gladys Ibarra, Alicia Senín · 2019 · Expert Review of Anticancer Therapy
61. Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta‐analysis of phase 3 randomized controlled trials
    Binod Dhakal, Ravi Kishore Narra, Smith Giri, Anikó Szabó, Timothy L. Smunt, Sanjoy Ghose, Lakshmi Kant Pathak, Madan Raj Aryal, Mehdi Hamadani, Saurabh Chhabra et al. · 2020 · Cancer
62. CD38: From Positive to Negative Expression after Daratumumab Treatment
    Bonell Patiño-Escobar, Roberto Ramos, Maximo Linares, Angie Mejía, Sebastián Alcalá · 2020 · Cureus
63. Outcomes of lenalidomide‐ or bortezomib‐based regimens in older patients with plasma cell myeloma
    Peter M. Barth, Smith Giri, John Leonard Reagan, Adam J. Olszewski · 2020 · American Journal of Hematology
64. Old and new generation immunomodulatory drugs in multiple myeloma
    Daniele Derudas, Francesca Capraro, Giovanni Martinelli, Claudio Cerchione · 2021 · Panminerva Medica
65. Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience
    Nadjoua Maouche, Bhuvan Kishore, Matthew W. Jenner, Kevin D. Boyd, Zara Bhatti, Sarah Anne Bird, Gurvin Chander, Rebecca Robinson, Grant D. Vallance, Mark Offer et al. · 2020 · Leukemia & lymphoma/Leukemia and lymphoma
66. Real-world effectiveness and safety of daratumumab, bortezomib and dexamethasone in relapsed/refractory multiple myeloma in Slovakia
    Ľubica Harvanová, Viera Štulajterová, Tomáš Guman et al. · 2021 · Neoplasma
67. A Systematic Review and Network Meta-analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide-refractory Multiple Myeloma
    Ghulam Rehman Mohyuddin, Jill Hampton, Muhammad Aziz, Sadik Khuder, Saad Ullah Malik, Brian Lee McClune, Al-Ola A. Abdallah · 2021 · Clinical Lymphoma Myeloma & Leukemia
68. Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma
    Margaux Lejeune, Elodie Duray, Matthias Peipp, Béatrice Clemenceau, Frédéric Baron, Yves P. Beguin, Jo Caers · 2021 · Cancers
69. The safety of daratumumab for the treatment of multiple myeloma
    María José Cejalvo, Paz Ribas, Javier de la Rubia · 2017 · Expert Opinion on Drug Safety
70. Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases
    Dimitrios C. Ziogas, Evangelos Terpos, Maria Gavriatopoulou, Magdalini Migkou, Despina Fotiou, Μαρία Ρούσσου, Nikolaos Kanellias, Ioanna P. Tatouli, Evangelos Eleutherakis‐Papaiakovou, Ioannis Panagiotidis et al. · 2017 · Leukemia & lymphoma/Leukemia and lymphoma
71. Utilization Patterns of Single Fraction Radiation Therapy for Multiple Myeloma
    Lucas Resende Salgado, Sanders Chang, Meng Ru, Erin L Moshier, Zahra Ghiassi–Nejad, Stanislav Lazarev, William Smith, Marcher Thompson, Kavita Vyas Dharmarajan · 2019 · Clinical Lymphoma Myeloma & Leukemia
72. The evolving role of maintenance therapy following autologous stem cell transplantation in multiple myeloma
    Almuth Maria Anni Merz, Maximilian Merz, Jens Hillengaß, Sarah A. Holstein, Philip L. McCarthy · 2019 · Expert Review of Anticancer Therapy
73. Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials
    Enrica Antonia Martino, Daniele Derudas, Elena Rossi et al. · 2024 · Haematologica
74. Real-World Treatment Outcomes of Different Sequencing Options with Daratumumab, Lenalidomide, and Dexamethasone in Patients with Transplant-Ineligible Multiple Myeloma in Japan
    Kazuhito Suzuki, Yuma Fujimori, Chika Sakai, Hiroaki Tsuchiya, Yosuke Koroki · 2025 · Cancers
75. Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myeloma
    Luqun Wang, Wei Cheng Yang, Yafei Wang, Ting Niu, Rong Fu, Yuping Zhong, Wenbin Qian, Kaiyang Ding, Kai Sun, Hong Liu et al. · 2025 · BMC Cancer
76. Anti-N-methyl-d-aspartate receptor encephalitis: insights and future treatment directions
    Yoji Hoshina, Tammy Smith, Melissa A. Wright, Gregory Scott Day, Maarten J. Titulaer, Stacey Lynn Clardy · 2025 · Trends in Molecular Medicine
77. Upfront Anti-CD38 Monoclonal Antibody-Based Quadruplet Therapy for Multiple Myeloma: A Systematic Review and Meta-Analysis of Clinical Trials
    Ioannis Ntanasis‐Stathopoulos, Charalampos Filippatos, Panagiotis Malandrakis, Vassilis Koutoulidis, Efstathios Kastritis, Evangelos Terpos, Meletios Athanasios Dimopoulos, Maria Gavriatopoulou · 2025 · Cancers
78. Real world data of the impact of first cycle daratumumab on multiple myeloma and AL amyloidosis services
    Rakesh Popat, Emma Dowling, Sufyan Achhala, Devanshi Pandit, Neil K. Rabin, Charalampia A. Kyriakou, Stephen Mackinnon, Kwee Yong, Ashutosh D. Wechalekar · 2017 · British Journal of Haematology
79. Immunotherapy: the good, the bad, the ugly, and the really ugly
    Donald R. Branch · 2019 · Transfusion
80. Do cytomegalovirus infections affect the daratumumab treatment course in multiple myeloma patients? – Literature review
    Luana Mota Ferreira, Jaderson Lima Cerezer, Mailine Gehrcke · 2020 · Hematology Transfusion and Cell Therapy
81. Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham’s Lymphangiomatosis: Review of the Literature
    Matthew H. Lee, Beth A. Martin, Haifaa Abdulhaq · 2022 · Case Reports in Hematology
82. Bispecific Antibodies for the Treatment of Multiple Myeloma
    Scott Ryan Goldsmith, Shawn Streeter, Fahrettin Covut · 2022 · Current Hematologic Malignancy Reports
83. Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis
    Silvia Mangiacavalli, Claudio Salvatore Cartia, Monica Galli, Sara Pezzatti, Angelo Belotti, Francesca Fazio, Roberto Mina, Magda Marcatti, Anna Maria Cafro, Renato Zambello et al. · 2022 · Haematologica
84. Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study
    Damian Mikulski, Pawel J. Robak, Wiktoria Ryżewska, Kamila Stańczak, Kacper Kościelny, Joanna Góra‐Tybor, Tadeusz Robak · 2022 · Journal of Clinical Medicine
85. Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003)
    Hongmei Jing, Yang Li, Junyuan Qi, Lugui Qiu, Chengcheng Fu, Junmin Li, Min Yang, Ming Qi, Ni Fan, Jia Ji et al. · 2022 · Annals of Hematology
86. Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
    Joshua Ryan Richter, Peggy L. Lin, Viviana García-Horton, Patricia Guyot, Erin Singh, Zheng‐Yi Zhou, Mark Sievert, Riley Taiji · 2023 · Cancer Medicine
87. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin
    Yutaka Shimazu, Junya Kanda, Satoru Kosugi, Tomoki� Ito, Hitomi Kaneko, Kazunori Imada, Yuji Shimura, Shin‐ichi Fuchida, Kentaro Fukushima, Hirokazu Tanaka et al. · 2023 · Scientific Reports
88. A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse
    Manisha Bhutani, David Foureau, Myra M Robinson, Fei Guo, Kateryna Fesenkova, Shebli Atrash, Barry A. Paul, Cindy Varga, Reed N. Friend, Mauricio Pineda‐Roman et al. · 2023 · Clinical Lymphoma Myeloma & Leukemia
89. Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies
    Anna Maria Sureda, Peter Dreger, Michael Russell Bishop, Nicolaus Martin Kröger, David Porter · 2018 · Bone Marrow Transplantation
90. Cellular immunotherapy as a therapeutic approach in multiple myeloma
    Jessica J. Liegel, David Avigan, Jacalyn M. Rosenblatt · 2018 · Expert Review of Hematology
91. Risk-Based Therapeutic Strategies
    Jill Corre, Hervé Avet‐Loiseau · 2019 · The Cancer Journal
92. Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses
    Justin R. Arnall, Donald C. Moore, Hailey Hill, Sarah Griffin, Maxine K. Mueller, Lesli A. Lavery, Peter Michael Voorhees, Saad Z. Usmani · 2019 · Leukemia & lymphoma/Leukemia and lymphoma
93. MPC-1 expression in myeloma cells is associated with the efficacy of bortezomib therapy
    Kazuya Kurihara, Noriyoshi Iriyama, Katsuhiro Miura, Y. Uchino, Hiromichi Takahashi, Masaru Nakagawa, Kazuhide Iizuka, Takashi Hamada, Takashi Koike, Yoshihiro Hatta et al. · 2019 · Medical Oncology
94. Pleural plasmacytomas – the role of radiotherapy
    Kheng‐Wei Yeoh, Saw M. Thitsar, Zubin Master, Yvonne Loh, Yunxin Chen, Chandramouli Nagarajan, Kah‐Ming Tin, David J. Cutter, Nabegh George Mikhaeel · 2020 · British Journal of Haematology
95. Comparative Effectiveness Research for CAR-T Therapies in Multiple Myeloma: Appropriate Comparisons Require Careful Considerations of Data Sources and Patient Populations
    Nina D. Shah, Matthew Sussman, Concetta Crivera, Satish Valluri, Jennifer Benner, Sundar Jagannath · 2021 · Clinical Drug Investigation
96. Retrospective study of treatment patterns and outcomes post‐lenalidomide for multiple myeloma in Canada
    Donna Ellen Reece, Esther Masih‐Khan, Eshetu G. Atenafu, Victor Hugo Jimenez-Zepeda, Arleigh B. Robertson McCurdy, Kevin Song, Richard LeBlanc, Michaël Sébag, Darrell J. White, Hannah Marie Cherniawsky et al. · 2021 · European Journal Of Haematology
97. China's potential role in humanitarian assistance
    Andrea Binder, Björn Conrad · 2009
98. ‘Fast but not so Furious’: Short observation time after subcutaneous Daratumumab administration is both a safe and cost-effective strategy
    James A. Davis, Heather Youngberg, Kelly J Gaffney · 2022 · Clinical Lymphoma Myeloma & Leukemia
99. A review of the current status of lenalidomide maintenance therapy in multiple myeloma in 2022
    Ravi Kumar Gupta, Ashish K Gupta, Jens Hillengaß, Sarah A. Holstein, Vera Jean Suman, Alankrita Taneja, Philip L. McCarthy · 2022 · Expert Review of Anticancer Therapy
100. The impact of current therapeutic options on the health-related quality of life of patients with relapse/refractory multiple myeloma: a systematic review of clinical studies
     Ademola Samuel Ojo, Mojisola O. Araoye, Ahmed Said Ali, Ravi Sarma · 2023 · Journal of Cancer Survivorship